Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Journal of the National Cancer Institute|June 29, 2007
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effectWenyu Jiang, Boris Freidlin, Richard Simon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005Edward L Korn, Boris Freidlin, Margaret Mooney
American Journal of Human Genetics|January 10, 2006
Robust genomic control for association studiesGang Zheng, Boris Freidlin, Joseph L Gastwirth
Clinical Trials (London, England)|April 29, 2010
A general inefficacy interim monitoring rule for randomized clinical trialsBoris Freidlin, Edward L Korn, Robert Gray
Clinical Trials (London, England)|September 15, 2021
Reply to Quartagno et alBoris Freidlin, Chen Hu, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other ApproachesMegan Othus, Boris Freidlin, Edward L Korn
Clinical Trials (London, England)|May 4, 2016
Information time scales for interim analyses of randomized clinical trialsBoris Freidlin, Megan Othus, Edward L Korn
Clinical Trials (London, England)|February 25, 2021
Are restricted mean survival time methods especially useful for noninferiority trials?Boris Freidlin, Chen Hu, Edward L Korn
JAMA|July 15, 2010
Bias and trials stopped early for benefitEdward L Korn, Boris Freidlin, Margaret Mooney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Complexities in interpretation of osteosarcoma clinical trial resultsSally Hunsberger, Boris Freidlin, Malcolm A Smith
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Journal of the National Cancer Institute|June 29, 2007
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effectWenyu Jiang, Boris Freidlin, Richard Simon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005Edward L Korn, Boris Freidlin, Margaret Mooney
American Journal of Human Genetics|January 10, 2006
Robust genomic control for association studiesGang Zheng, Boris Freidlin, Joseph L Gastwirth
Clinical Trials (London, England)|April 29, 2010
A general inefficacy interim monitoring rule for randomized clinical trialsBoris Freidlin, Edward L Korn, Robert Gray
Clinical Trials (London, England)|September 15, 2021
Reply to Quartagno et alBoris Freidlin, Chen Hu, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other ApproachesMegan Othus, Boris Freidlin, Edward L Korn
Clinical Trials (London, England)|May 4, 2016
Information time scales for interim analyses of randomized clinical trialsBoris Freidlin, Megan Othus, Edward L Korn
Clinical Trials (London, England)|February 25, 2021
Are restricted mean survival time methods especially useful for noninferiority trials?Boris Freidlin, Chen Hu, Edward L Korn
JAMA|July 15, 2010
Bias and trials stopped early for benefitEdward L Korn, Boris Freidlin, Margaret Mooney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Complexities in interpretation of osteosarcoma clinical trial resultsSally Hunsberger, Boris Freidlin, Malcolm A Smith
Pageof 12